Literature DB >> 9880848

[Prevention of thromboembolism with low-molecular-weight heparin in ambulatory surgery and unoperated surgical and orthopedic patients].

J Harenberg1, L Piazolo, F Misselwitz.   

Abstract

Prophylaxis of thromboembolism is now well established in orthopaedic outpatients with plaster cast and after elective hip surgery. The present study was undertaken to evaluate the safety of out-of-hospital prevention of venous thromboembolism and to determine the incidence of thromboembolic complications in orthopaedic and surgical patients with or without surgical intervention on an out-patient basis during prophylaxis of thromboembolism with low-molecular-weight heparin and to study the feasibility of this treatment regimen. The treatment period was 1-4 weeks (mean 17 days). Main indications for prophylaxis of thromboembolism were arthroscopy and surgical or non-surgical intervention of bone fractures of the lower leg. The incidence of clinically diagnosed venous thromboembolism was 11/1604 (0.7%) in operated and 8/1017 (0.8%) in non-operated patients. Pulmonary embolism occurred twice in operated patients (0.1%) and in none of the non-operated patients. Minor bleeding complications were rare and major bleeding complications did not occur. Haematomas at the injection site occurred in only 4% of patients. Thrombocytopenia did not occur in any patient. The present study demonstrates the feasibility and safety to prophylaxis of thromboembolism with low-molecular-weight heparin in orthopaedic operated and non-operated out-patients with various orthopaedic or surgical diseases leading to immobilization. The incidence of clinically apparent thromboembolic complications is low and similar to medical bedridden inpatients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9880848

Source DB:  PubMed          Journal:  Zentralbl Chir        ISSN: 0044-409X            Impact factor:   0.942


  2 in total

Review 1.  Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.

Authors:  K Wellington; K McClellan; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization.

Authors:  Aniek Ag Zee; Kelly van Lieshout; Maaike van der Heide; Loes Janssen; Heinrich Mj Janzing
Journal:  Cochrane Database Syst Rev       Date:  2017-08-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.